SUBLICENSE AGREEMENTSublicense Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS SUBLICENSE AGREEMENT (this “Agreement”), dated as of December 21, 2007 (the “Effective Date”), is made by and among CELL THERAPEUTICS, INC., a Washington corporation (“CTI”), BIOGEN IDEC INC., a Delaware corporation (“BIIB”), and CORIXA CORPORATION, a Delaware corporation (“CORIXA”), COULTER PHARMACEUTICAL, INC., a Delaware corporation (“COULTER”), THE REGENTS OF THE UNIVERSITY OF MICHIGAN, a Michigan constitutional corporation (“MICHIGAN”) and SMITHKLINE BEECHAM CORPORATION doing business as GLAXOSMITHKLINE, a Pennsylvania corporation (“GSK”) (CORIXA, COULTER, MICHIGAN, and GSK, collectively, “LICENSORS”).
LICENSE AGREEMENTLicense Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
THIS AGREEMENT, effective this 23rd day of May, 2006, between Merck Eprova AG, a Swiss corporation organized and existing under the laws of Switzerland and with its principal place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland (“EPRO”), and Spectrum Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 157 Technology Drive, Irvine, California 92688, United States (“Spectrum”). EPRO and Spectrum may hereinafter each be referred to as a Party or collectively as the Parties.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT, AS AMENDED. OMNIBUS AMENDMENT TO...Spectrum Pharmaceuticals Inc • November 9th, 2012 • Pharmaceutical preparations
This Omnibus Amendment to Zevalin Supply Arrangements (this “Amendment”) is made effective as of the 1st day of October, 2012 by and between Biogen Idec US Corporation, a Massachusetts corporation (“Biogen Idec”), on one hand, and RIT Oncology, LLC, a Delaware limited liability company and wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. (“RIT”), and Spectrum Pharmaceuticals Cayman, L.P., a Cayman exempted limited partnership and wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. (“Cayman”) (RIT and Cayman, collectively, “Spectrum”), on the other hand. Biogen Idec and Spectrum are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
THIS AGREEMENT (“Agreement”) is made and entered into this 23rd day of May 2006, (“Effective Date”) by and between Merck Eprova AG, a Swiss corporation, having a place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland (“EPRO”) and Spectrum Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 157 Technology Drive, Irvine, California, 92618, United States (“SPECTRUM”). EPRO and SPECTRUM may hereinafter each be referred to as a “Party” or collectively as the “Parties”. Capitalized terms used in this Agreement shall have the meaning set forth herein or in the License Agreement (as defined below).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT, AS AMENDED. SUPPLY AGREEMENTSupply Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS SUPPLY AGREEMENT (“THE SUPPLY AGREEMENT”) is made effective as of the 9th day of June, 1999 (the “Effective Date”) by and between IDEC PHARMACEUTICALS CORPORATION, a Delaware corporation, having its principal place of business at 11011 Torreyana Road, San Diego, California 92121(“IDEC”) and SCHERING AKTIENGESELLSCHAFT, a German corporation, having its principal place of business at Müllerstrasse 178, D-13342 Berlin, Germany (“SCHERING”). IDEC and SCHERING are sometimes referred to herein individually as a “Party” and collectively as the “Parties”, and references to “IDEC” shall include its Affiliates.
LICENSE AGREEMENTLicense Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
THIS LICENSE AGREEMENT (this “Agreement”), dated as of December 21, 2007 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“CTI”), and BIOGEN IDEC INC., a Delaware corporation (“BIIB”).
LICENSE-BACK AGREEMENTLicense-Back Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
THIS LICENSE-BACK AGREEMENT (this “Agreement”), dated as of December 21, 2007 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“CTI”), and BIOGEN IDEC INC., a Delaware corporation (“BIIB”).
SUBLICENSE AGREEMENTSublicense Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS SUBLICENSE AGREEMENT (this “Agreement”), dated as of December 21, 2007 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“CTI”), and BIOGEN IDEC INC., a Delaware corporation (“BIIB”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT, AS AMENDED. SUBLICENSE AGREEMENTSublicense Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • California
Pursuant to Fed. R. Civ. P. 41(a)(1), Plaintiff, IDEC Pharmaceuticals, Inc. (“IDEC”), and defendants, SmithKline Beecham, Corp., Glaxo Wellcome Inc. and Burroughs Wellcome Company (collectively, “GlaxoSmithKline”), through their undersigned counsel, hereby stipulate to dismissal with prejudice of all of the claims asserted in this action, each party to bear its own costs, expenses and attorneys’ fees. IDEC and GlaxoSmithKline further stipulate and agree that the Court shall retain jurisdiction over this matter for a period of one year following the filing date of this Stipulation of Dismissal with Prejudice.
EMPLOYMENT AGREEMENTEmployment Agreement • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • Nevada
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into the 28th day of August, 2012 by and between Spectrum Pharmaceuticals, Inc. (hereinafter referred to as the “Company”), and Joseph Kenneth Keller (“Executive”). In consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:
